.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,354,772

« Back to Dashboard

Claims for Patent: 5,354,772

Title: Indole analogs of mevalonolactone and derivatives thereof
Abstract:Compounds of the formula ##STR1## wherein one of R and R.sub.o is ##STR2## and the other is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom, C.sub.3-6 cycloalkyl or phenyl-(CH.sub.2).sub.m --, wherein R.sub.4 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R.sub.5 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R.sub.5a is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, and m is 1, 2 or 3, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen, R.sub.5a must be hydrogen when R.sub.5 is hydrogen, not more than one of R.sub.4 and R.sub.5 is trifluoromethyl, not more than one of R.sub.4 and R.sub.5 is phenoxy, and not more than one of R.sub.4 and R.sub.5 is benzyloxy, R.sub.2 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.3-6 cycloalkyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R.sub.3 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R.sub.3 must be hydrogen when R.sub.2 is hydrogen, not more than one of R.sub.2 and R.sub.3 is trifluoromethyl, not more than one of R.sub.2 and R.sub.3 is phenoxy, and not more than one of R.sub.2 and R.sub.3 is benzyloxy, X is --(CH.sub.2).sub.n -- or --CH.dbd.CH--, wherein n is 0, 1, 2 or 3, and Z is ##STR3## wherein R.sub.6 is hydrogen or C.sub.1-3 alkyl, and R.sub.7 is hydrogen, R.sub.7b or M, wherein R.sub.7b is a physiologically acceptable and hydrolyzable ester group, and M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level, and therefore, in the treatment of hyperliopoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.
Inventor(s): Kathawala; Faizulla G. (Mountain Lakes, NJ)
Assignee: Sandoz Pharm. Corp. (E. Hanover, NJ)
Application Number:08/157,595
Patent Claims: 1. A compound of the formula ##STR223## wherein one of R and R.sub.o is and the other is ##STR224## and the other is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom, C.sub.1-3 cycloalkyl or phenyl-(CH.sub.2).sub.m --,

wherein R.sub.4 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5a is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro, or chloro, and

m is 1, 2 or 3, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen, R.sub.5a must be hydrogen when R.sub.5 is hydrogen, not more than one of R.sub.4 and R.sub.5 is trifluoromethyl, not more than one of R.sub.4 and R.sub.5 is phenoxy, and not more than one of R.sub.4 and R.sub.5 is benzyloxy,

R.sub.2 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.3-6 cycloalkyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.3 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R.sub.3 must be hydrogen when R.sub.2 is hydrogen, not more than one of R.sub.2 and R.sub.3 is trifluoromethyl, not more than one of R.sub.2 and R.sub.3 is phenoxy, and not more than one of R.sub.2 and R.sub.3 is benzyloxy,

X is --(CH.sub.2).sub.n -- or --CH.dbd.CH--, wherein n is 0, 1, 2 or 3, and

Z is ##STR225## wherein R.sub.6 is hydrogen or C.sub.1-3 alkyl, and R.sub.7 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, benzyl, or M, wherein M is a cation.

2. A compound according to claim 1 wherein M is a pharmaceutically acceptable cation.

3. A compound according to claim 2 having the formula ##STR226## wherein R.sub.1 is primary or secondary C.sub.1-3 alkyl not containing an asymmetric carbon atom, C.sub.3-6 cycloalkyl or phenyl-(CH.sub.2).sub.m --, wherein m is 1, 2 or 3,

R.sub.2 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.3-6 cycloalkyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.3 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R.sub.3 must be hydrogen when R.sub.2 is hydrogen, not more than one of R.sub.2 and R.sub.3 is trifluoromethyl, not more than one of R.sub.2 and R.sub.3 is phenoxy, and not more than one of R.sub.2 and R.sub.3 is benzyloxy,

R.sub.4 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5a is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen, R.sub.5a must be hydrogen when R.sub.5 is hydrogen, not more than one of R.sub.4 and R.sub.5 is trifluoromethyl, not more than one of R.sub.4 and R.sub.5 is phenoxy, and not more than one of R.sub.4 and R.sub.5 is benzyloxy,

R.sub.6 is hydrogen or Cl.sub.1-3 alkyl,

R.sub.7 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, benzyl or M, wherein M is a pharmaceutically acceptable cation, and

X is --(CH.sub.2).sub.n -- or --CH.dbd.CH--, wherein n is 0, 1, 2 or 3.

4. A compound according to claim 3

wherein

R.sub.1 is primary or secondary C.sub.1-5 alkyl not containing an asymmetric carbon atom,

R.sub.2 is hydrogen or C.sub.1-3 alkyl,

R.sub.3 is hydrogen or Cl.sub.1-3 alkyl, with the proviso that R.sub.3 must be hydrogen when R.sub.2 is hydrogen,

R.sub.4 is hydrogen, C.sub.1-2 alkyl, trifluoromethyl or fluoro,

R.sub.5 is hydrogen or methyl,

R.sub.5a is hydrogen or methyl with the proviso that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen and R.sub.5 must be hydrogen when R.sub.5 is hydrogen,

R.sub.6 is hydrogen or methyl,

R.sub.7 is hydrogen, C.sub.1-2 alkyl or M, wherein M is a pharmaceutically acceptable cation, and

X is --CH.sub.2 CH.sub.2 -- or --CH.dbd.CH--.

5. A compound according to claim 3

wherein

R.sub.1 is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom,

R.sub.2 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.3 is hydrogen, C.sub.1-3 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, with the proviso that R.sub.3 must be hydrogen when R.sub.2 is hydrogen,

R.sub.4 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5 is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro,

R.sub.5a is hydrogen or methyl, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen and R.sub.5a must be hydrogen when R.sub.5 is hydrogen,

R.sub.6 is hydrogen or C.sub.1-2 alkyl,

R.sub.7 is hydrogen, C.sub.1-3 alkyl or M, wherein M is a pharmaceutically acceptable cation, and

X is --(CH.sub.2).sub.m -- or ##STR227## wherein m is 1, 2 or 3.

6. A compound according to claim 5

wherein

R.sub.1 is C.sub.1-3 alkyl,

R.sub.2 is hydrogen, C.sub.1-3 alkyl, methoxy, fluoro, chloro or 4-, 5- or 6-benzyloxy,

R.sub.3 is hydrogen or C.sub.1-3 alkyl, with the proviso that R.sub.3 must be hydrogen when R.sub.2 is hydrogen,

R.sub.4 is hydrogen, methyl, methoxy, fluoro or chloro,

R.sub.5 is hydrogen, methyl, methoxy, fluoro or chloro,

R.sub.5a is hydrogen or methyl, with the proviso that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen and R.sub.5a must be hydrogen when R.sub.5 is hydrogen,

R.sub.6 is hydrogen,

R.sub.7 is hydrogen, C.sub.1-2 alkyl or M, wherein M is a pharmaceutically acceptable cation, and

X is --CH.sub.2 CH.sub.2 -- or ##STR228##

7. A compound according to claim 6 having the formula ##STR229## wherein M.sup..sym. is a pharmaceutically acceptable cation.

8. A compound to claim 7 in racemic erythro form.

9. The compound according to claim 7 having the formula ##STR230##

10. The compound according to claim 9 having the 3R,5S configuration.

11. The compound of the formula ##STR231## in racemic erythro form.

12. A compound according to claim 2 having the formula ##STR232## wherein R.sub.1 is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom, C.sub.3-6 cycloalkyl or phenyl-(CH.sub.2).sub.m --, wherein m is 1, 2 or 3,

R.sub.2 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.3-6 cycloalkyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.3 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R.sub.3 must be hydrogen when R.sub.2 is hydrogen, not more than one of R.sub.2 and R.sub.3 is trifluoromethyl, not more than one of R.sub.2 and R.sub.3 is phenoxy, and not more than one of R.sub.2 and R.sub.3 is benzyloxy,

R.sub.4 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5a is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen, R.sub.5a must be hydrogen when R.sub.5 is hydrogen, not more than one of R.sub.4 and R.sub.5 is trifluoromethyl, not more than one of R.sub.4 and R.sub.5 is phenoxy, and not more than one of R.sub.4 and R.sub.5 is benzyloxy,

R.sub.6 is hydrogen or C.sub.1-3 alkyl, and

X is --(CH.sub.2).sub.n -- or --CH.dbd.CH--, wherein n is 0, 1, 2 or 3.

13. A compound according to claim 12

wherein

R.sub.1 is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom,

R.sub.2 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.3 is hydrogen, C.sub.1-3 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, with the proviso that R.sub.3 must be hydrogen when R.sub.2 is hydrogen,

R.sub.4 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5 is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro,

R.sub.5a is hydrogen or methyl, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen and R.sub.5a must be hydrogen when R.sub.5 is hydrogen,

R.sub.6 is hydrogen or C.sub.1-2 alkyl, and

X is ##STR233## wherein m is 1, 2 or 3.

14. A compound according to claim 2 having the formula ##STR234## wherein R.sub.1 is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom, C.sub.3-6 cycloalkyl or phenyl-(CH.sub.2).sub.m --, wherein m is 1, 2 or 3,

R.sub.2 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.3-6 cycloalkyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.3 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R.sub.3 must be hydrogen when R.sub.2 is hydrogen, not more than one of R.sub.2 and R.sub.3 is trifluoromethyl, not more than one of R.sub.2 and R.sub.3 is phenoxy, and not more than one of R.sub.2 and R.sub.3 is benzyloxy,

R.sub.4 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5a is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen, R.sub.5a must be hydrogen when R.sub.5 is hydrogen, not more than one of R.sub.4 and R.sub.5 is trifluoromethyl, not more than one of R.sub.4 and R.sub.5 is phenoxy, and not more than one of R.sub.4 and R.sub.5 is benzyloxy,

R.sub.6 is hydrogen or C.sub.1-3 alkyl,

R.sub.7 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, benzyl or M, wherein M is a pharmaceutically acceptable cation, and

X is --(CH.sub.2).sub.n -- or --CH.dbd.CH--, wherein n is 0, 1, 2 or 3.

15. A compound according to claim 14

wherein

R.sub.1 is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom,

R.sub.2 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.3 is hydrogen, C.sub.1-3 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, with the proviso that R.sub.3 must be hydrogen when R.sub.2 is hydrogen,

R.sub.4 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5 is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro,

R.sub.5a is hydrogen or methyl, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen and R.sub.5a must be hydrogen when R.sub.5 is hydrogen,

R.sub.6 is hydrogen or C.sub.1-2 alkyl,

R.sub.7 is hydrogen, C.sub.1-3 alkyl or M, wherein M is a pharmaceutically acceptable cation, and

X is ##STR235## wherein m is 1, 2 or 3.

16. A compound according to claim 2 having the formula ##STR236## wherein R.sub.1 is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom, C.sub.3-6 cycloalkyl or phenyl-(CH.sub.2).sub.m --, wherein m is 1, 2 or 3,

R.sub.2 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.3-6 cycloalkyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.3 is hydrogen, C.sub.1-3 alkyl C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R.sub.3 must be hydrogen when R.sub.2 is hydrogen, not more than one of R.sub.2 and R.sub.3 is trifluoromethyl, not more than one of R.sub.2 and R.sub.3 is phenoxy, and not more than one of R.sub.2 and R.sub.3 is benzyloxy,

R.sub.4 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5a is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen, R.sub.5a must be hydrogen when R.sub.5 is hydrogen, not more than one of R.sub.4 and R.sub.5 is trifluoromethyl, not more than one of R.sub.4 and R.sub.5 is phenoxy, and not more than one of R.sub.4 and R.sub.5 is benzyloxy,

R.sub.6 is hydrogen or C.sub.1-3 alkyl, and

X is --(CH.sub.2).sub.n -- or --CH.dbd.CH--, wherein n is 0, 1, 2 or 3.

17. A compound according to claim 16

wherein

R.sub.1 is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom,

R.sub.2 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.3 is hydrogen, C.sub.1-3 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, with the proviso that R.sub.3 must be hydrogen when R.sub.2 is hydrogen,

R.sub.4 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5 is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro,

R.sub.5a is hydrogen or methyl, with the provisos that both R.sub.5 and R.sub.5a a must be hydrogen when R.sub.4 is hydrogen and R.sub.5a must be hydrogen when R.sub.5 is hydrogen,

R.sub.6 is hydrogen or C.sub.1-2 alkyl, and

X is ##STR237## wherein m is 1, 2 or 3.

18. A pharmaceutical composition comprising an effective amount of a compound according to claim 2 and a pharmaceutically acceptable carrier, said effective amount being an amount sufficient to inhibit cholesterol biosynthesis in a mammal.

19. A pharmaceutical composition according to claim 18 wherein the compound is a compound of the formula ##STR238## wherein M.sup..sym. is a pharmaceutically acceptable cation.

20. A pharmaceutical composition according to claim 19 wherein the compound is a compound of the formula ##STR239## wherein M.sup..sym. is a pharmaceutically acceptable cation, in racemic erythro form.

21. A pharmaceutical composition according to claim 20 wherein the compound is the compound of the formula ##STR240## in racemic erythro form.

22. A method of inhibiting cholesterol biosynthesis comprising administering to a mammal in need of such treatment an effective amount of a compound according to claim 2, said effective amount being an amount effective for inhibiting cholesterol biosynthesis.

23. A method of inhibiting cholesterol biosynthesis according to claim 22 wherein the compound is a compound of the formula ##STR241## wherein M.sup..sym. is a pharmaceutically acceptable cation.

24. A method of inhibiting cholesterol biosynthesis according to claim 23 wherein the compound is a compound of the formula ##STR242## wherein M.sup..sym. is a pharmaceutically acceptable cation, in racemic erythro form.

25. A method of inhibiting cholesterol biosynthesis according to claim 24 wherein the compound is the compound of the formula ##STR243## in racemic erythro form.

26. A method of treating atherosclerosis comprising administering to a mammal in need of such treatment an effective amount of a compound according to claim 2, said effective amount being an amount effective for the treatment of atherosclerosis.

27. A method of treating atherosclerosis according to claim 26 wherein the compound is a compound of the formula ##STR244## wherein R.sub.1 is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom, C.sub.3-6 cycloalkyl or phenyl-(CH.sub.2).sub.m --, wherein m is 1, 2 or 3,

R.sub.2 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.3-6 cycloalkyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.3 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R.sub.3 must be hydrogen when R.sub.2 is hydrogen, not more than one of R.sub.2 and R.sub.3 is trifluoromethyl, not more than one of R.sub.2 and R.sub.3 is phenoxy, and not more than one of R.sub.2 and R.sub.3 is benzyloxy,

R.sub.4 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,

R.sub.5a is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen, R.sub.5a must be hydrogen when R.sub.5 is hydrogen, not more than one of R.sub.4 and R.sub.5 is trifluoromethyl, not more than one of R.sub.4 and R.sub.5 is phenoxy, and not more than one of R.sub.4 and R.sub.5 is benzyloxy,

R.sub.6 is hydrogen or C.sub.1-3 alkyl,

R.sub.7 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, benzyl or M, wherein M is a pharmaceutically acceptable cation, and

X is --(CH.sub.2).sub.n -- or --CH.dbd.CH-- wherein n is 0, 1, 2 or 3.

28. A method of treating atherosclerosis according to claim 27 wherein the compound is a compound of the formula ##STR245## wherein M.sup..sym. is a pharmaceutically acceptable cation.

29. A method of treating atherosclerosis according to claim 28 wherein the compound is a compound of the formula ##STR246## wherein M.sup..sym. is a pharmaceutically acceptable cation, in racemic erythro form.

30. A method of treating atherosclerosis according to claim 29 wherein the compound is the compound of the formula ##STR247## in racemic erythro form.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc